AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research
An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II…
An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II…
Scotland has a thriving life sciences ecosystem with strengths in oncology, genetic engineering, and industrial…
Besides struggling with ambitious New Year’s resolutions and post-holiday diets, January is a time where…
We love hearing from our readers, and we listen to what they like! Here are…
The Alzheimer’s field has been hit with a number of failures. I spoke to the…
Before the “who to recruit” phase, an important question is “where?” We ran through the…
Biotech is one of the main forces driving the development of effective therapies to treat neurological and…
The much-anticipated results of TauRx's Phase III trial for Alzheimer's disease have finally been disclosed. Despite…
What updates have occurred in the Neurodegenerative disease field as of late? New appointments by…
Looking forward to 2016, I wondered which Biotechs I would watch closely. Here's my list…
Takeda Cambridge (the UK subsidiary of global biotech Takeda Pharmaceuticals) will now collaborate with University…
Monday: Manfred Horst on MSD, Biosimilars, KEYTRUDA and Merck & Co.’s rich history Tuesday: An Insider’s experience…